Complement vs FcRn MG Meta
(2026)Objective
To compare the efficacy and safety of complement inhibitors versus FcRn blockers in generalized AChR antibody-positive myasthenia gravis by pooling data across randomized controlled trials of these targeted biologics.
Study Summary
• Both targeted biologic classes were evaluated for MG-ADL/QMG response and adverse-event profiles
• Specific pooled effect estimates and head-to-head comparative magnitudes were not reported in the available source text
Intervention
Complement inhibitors versus FcRn (neonatal Fc receptor) blockers
Inclusion Criteria
Patients with generalized AChR antibody-positive myasthenia gravis enrolled in randomized controlled trials of complement inhibitors or FcRn blockers
Study Design
Arms: Complement inhibitors vs FcRn blockers (pooled across RCTs)
Patients per Arm: Not reported in source
Outcome
• Assessed adverse events for both drug classes
• Examined the relative positioning of the two biologic classes; specific quantitative results not provided in source
Bottom Line
This meta-analysis pooled RCT data to compare complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis across efficacy (MG-ADL/QMG) and safety endpoints; specific pooled effect estimates and the final comparative conclusion were not provided in the available source text.
Major Points
- Meta-analysis comparing two targeted biologic classes — complement inhibitors and FcRn blockers — in generalized AChR antibody-positive myasthenia gravis.
- Efficacy assessed via MG-ADL and QMG response.
- Safety assessed via adverse events.
- Aimed to define the relative positioning of complement inhibition versus FcRn blockade; specific quantitative pooled results were not available in the source text.
Study Design
- Study Type
- Meta-analysis of randomized controlled trials
- Randomization
- No
Primary Outcome
Definition: MG-ADL and QMG response to complement inhibitors versus FcRn blockers
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| - |
Citation
Journal of Neurology. April 2026. doi:10.1007/s00415-026-13778-1